Wide Ranks

MOLN

Molecular Partners AG

5.83

Top Statistics
Market Cap 216 M Forward PE -3.62 Revenue Growth -73.20 %
Current Ratio 14.33 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -0.8470 Enterprise / Revenue 8.77 Price To Sales Trailing12 Months 36.07
Profitability
Profit Margins 0.00 % Operating Margins -2142.29 %
Balance Sheet
Total Cash 143 M Total Cash Per Share 4.33 Total Debt 2 M
Total Debt To Equity 1.98 Current Ratio 14.33 Book Value Per Share 4.18
All Measures
Short Ratio 161.00 % Message Board Id finmb_32677064 Fax 41 44 755 77 07
Shares Short Prior Month 33492 Return On Equity -0.3737 City Schlieren
Uuid 3b1227e2-09aa-3330-8282-b0e2c7493dad Previous Close 5.71 First Trade Date Epoch Utc 1 B
Book Value 4.18 Beta 0.5370 Total Debt 2 M
Volume 1788 Price To Book 1.39 Fifty Two Week Low 3.32
Total Cash Per Share 4.33 Total Revenue 6 M Shares Short Previous Month Date 1 B
Target Median Price 8.65 Max Age 86400 Sand P52 Week Change 0.3133
Operating Margins -2142.29 % Target Mean Price 9.33 Net Income To Common -62591000
Short Percent Of Float 0.0022 Implied Shares Outstanding 37 M Trailing Peg Ratio None
Last Fiscal Year End 1 B Average Daily Volume10 Day 11640 Average Volume10days 11640
Total Cash 143 M Next Fiscal Year End 1 B Revenue Per Share 0.1820
Trailing PE 0.0000 Date Short Interest 1 B Most Recent Quarter 1 B
Regular Market Previous Close 5.71 Target Low Price 4.55 Gmt Off Set Milliseconds -18000000
Fifty Day Average 5.40 Open 5.83 Free Cashflow -38458248
Dividend Yield 0.00 % Return On Assets -0.2117 Time Zone Short Name EST
Trailing Eps -2.13 Day Low 5.79 Address1 Wagistrasse 14
Shares Outstanding 36 M Price Hint 2 Target High Price 14.79
Website https://www.molecularpartners.com 52 Week Change 0.3881 Average Volume 18139
Forward Eps -1.84 Recommendation Key none Compensation As Of Epoch Date 1 B
Quick Ratio 1408.10 % Is_sp_500 False Regular Market Day High 5.83
Profit Margins 0.00 % Debt To Equity 1.98 Fifty Two Week High 12.70
Day High 5.83 Shares Short 57949 Regular Market Open 5.83
Industry Key biotechnology Earnings Growth 0.00 % Enterprise To Revenue 8.77
Revenue Growth -73.20 % Shares Percent Shares Out 0.0016 Operating Cashflow -62041000
Currency USD Time Zone Full Name America/New_York Market Cap 216 M
Is_nasdaq_100 False Zip 8952 Quote Type EQUITY
Industry Biotechnology Long Name Molecular Partners AG Regular Market Day Low 5.79
Held Percent Institutions 0.0531 Current Price 5.83 Enterprise To Ebitda -0.8470
Financial Currency CHF Current Ratio 14.33 Industry Disp Biotechnology
Number Of Analyst Opinions 3 Country Switzerland Float Shares 6 M
Two Hundred Day Average 5.20 Enterprise Value 52 M Price To Sales Trailing12 Months 36.07
Forward PE -3.62 Regular Market Volume 1788 Ebitda -62162000
Exchange NMS
Go to Yahoo Finance Go to Seeking Alpha 
Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland.

The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia.

It also develops Switch-DARPin platform, a multispecific cKIT x CD16a x CD47 Switch-DARPin program for targeted and conditional immune cell activation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors.

It has license and research collaboration agreements with Novartis Pharma AG to develop DARPin-conjugated radioligand therapies; and collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics.

Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.